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Abstract 
No consensus exists regarding the role of radiotherapy in the management of gynecologic cancer in nonagenar‑
ian patients. We retrospectively reviewed the outcomes of 19 consecutive nonagenarian patients with gynecologic 
cancer (6 endometrial cancers, 6 cervical cancers, 4 vulvar cancers, and 3 vaginal cancers) who were treated with 
radiotherapy. Radiotherapy was performed mainly in a palliative setting (n = 12; 63.2%), with a median dose of 45 Gy 
(range, 6–76 Gy). Infrequent major acute or late toxicities were reported. Among 19 patients, 9 (47.4%) experienced 
tumor progression, 5 (26.3%) experienced complete response, 2 (10.5%) experienced stable disease and/or partial 
response. At last follow‑up, 12 patients (63.2%) had died; most deaths (n = 9) occurred because of the cancer. These 
results suggest that radiotherapy is feasible in the treatment of nonagenarian patients with gynecologic cancer.
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Background
Radiotherapy is a cornerstone in the management of 
gynecologic cancer. Because patients 65  years of age 
or older are often excluded from clinical trials, little 
is known about the therapeutic index (efficacy/toxic-
ity ratio) of radiotherapy in the geriatric population [1]. 
For patients at high risk of local recurrence or who have 
unresectable or locally advanced disease, radiotherapy 
can be performed with the intent to cure [2–6]. Radio-
therapy can also be performed in a palliative setting. A 
few studies reported radiotherapy-caused complications 
in nonagenarian patients, but data on efficacy are still 
scarce. The objective of the present study was to report 
efficacy and toxicity data on the radiotherapy treatment 
of nonagenarian patients with gynecologic cancer.
Patients and methods
This retrospective study was conducted at two public 
and two private comprehensive cancer centers in France. 
Institutional review boards approved the study, which 
was conducted in compliance with the Declaration of 
Helsinki.
Patient population
We reviewed the medical records of consecutive nonage-
narian patients who received external-beam radiotherapy 
for the treatment of gynecologic cancer between 2003 
and 2012. Patient, tumor, and radiotherapy characteris-
tics were analyzed. The total biological equivalent dose 
in 2-Gy fractions (EQD2) was calculated using the lin-
ear quadratic model and an alpha/beta ratio of 10 Gy for 
tumors.
Toxicity evaluation
Patients were assessed for toxicity every week during the 
radiotherapy treatment and every 6  months thereafter. 
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Toxicities were graded using the Common Terminology 
Criteria for Adverse Events (version 4.0). Toxicities that 
occurred within 6 months of the beginning of radiother-
apy treatment were considered acute toxicities; toxicities 
that occurred after 6  months were considered late tox-
icities. Follow-up and survival durations were calculated 
from receipt of the last radiotherapy fraction.
Results
Patient characteristics
We analyzed the data of 19 nonagenarian patients with 
gynecologic cancer. At the time of radiotherapy treat-
ment, the patients’ median age was 91.4  years (range, 
90.0–98.6 years). Before radiotherapy, 11 patients (57.9%) 
had an Eastern Cooperative Oncology Group Perfor-
mance Status score of 2 or higher. Nine patients (47.4%) 
were nursing home residents. Among the 19 patients, 
histologic diagnosis revealed 6 (31.6%) endometrial can-
cers, 6 (31.6%) cervical cancers, 4 (21.0%) vulvar cancer, 
and 3 (15.8%) vaginal cancers; primarily 15 (78.9%) with 
a locally advanced tumor (T3–T4 or N+) or metastatic 
disease. Seven patients (36.8%) underwent surgery before 
radiotherapy, and one patient (5.3%) had previously 
received radiotherapy for the same indication. Patient 
characteristics are shown in Table 1.
Radiotherapy characteristics
Three-dimensional conformal radiotherapy was used 
for palliation, and intensity-modulated radiotherapy 
was used for curative intent. The median delivered dose 
was 45 Gy (range, 6–76 Gy), and the median EQD2 was 
44.2 Gyα/β = 10 (range, 8–84 Gyα/β = 10). The median num-
ber of fractions was 18 (range, 1–36 fractions), and the 
median dose per fraction was 3 Gy (range, 1.5–6 Gy). Pal-
liative treatments were mainly hemostatic radiotherapy 
(8 of 19, 42.1%), followed by decompression radiotherapy 
(1 of 19, 5.3%) and postoperative radiotherapy (1 of 19, 
5.3%); the intent of radiotherapy was not reported in two 
patients (10.5%). Radiotherapy was performed with the 
intent to cure for seven patients (36.8%).
Efficacy and toxicity data
Median follow-up time was 18  weeks (range, 
0–116  weeks). At last follow-up, seven patients (36.8%) 
achieved tumor control (defined as stable disease and/
or partial response and/or complete response), including 
five complete responses; 12 patients (63.2%) treated with 
radiotherapy for palliative intent died, mainly because of 
disease progression (n = 9; 47.4%).
One patient who underwent 15 Gy of irradiation (total 
prescribed dose: 50 Gy) developed grade 5 bladder perfo-
ration and peritonitis and died after surgery for stage IV 
endometrial cancer); this represented 8.3% (1 of 12) of all 
deaths. One patient (5.3%) who underwent 44 Gy of irra-
diation (total prescribed dose for cervical cancer: 44 Gy) 
developed grade 4 diarrhea, and one patient (5.3%) devel-
oped grade 3 diarrhea. Two patients (10.5%) developed 
grade 2 asthenia, and one patient (5.3%) developed grade 
2 epithelitis. There were two (10.5%) treatment disrup-
tions: one caused by grade 5 toxicity, the other caused by 
grade 3 toxicity. One late grade 2 toxicity was observed 
(lower limb edema).
Discussion
Based on these real-life findings, radiotherapy seems 
feasible in nonagenarian patients, either with intent to 
cure or in palliative setting. In this study, we retrospec-
tively assessed the safety and efficacy of radiotherapy for 
19 nonagenarian patients with gynecologic cancer. We 
observed only infrequent infield toxicities (5.3% grade 5, 
5.3% grade 4, and 5.3% grade 3). At last follow-up, disease 
was controlled in 36.8% of the patients. Currently, little 
is known about the therapeutic index (efficacy/toxicity 
ratio) of radiotherapy in patients 65 years of age or older. 
Toxicities in small populations of geriatric patients were 
reported, but these studies employed outdated radio-
therapy techniques [7, 8]. To our knowledge, our study 
is one of the largest to analyze the effects of radiother-
apy on nonagenarian patients with gynecologic cancer. 
As expected, hypofractionated techniques were widely 
used, since they reduce acute toxicities (in cell popula-
tions with a high turnover, such as mucosal membranes) 
Table 1 Characteristics of  19 nonagenarian patients with   
gynecologic cancer
PS performance status; N+ positive lymph node
Characteristic No. of patients (%)
PS score
 0–1 8 (42.1)
 2 5 (26.3)
 3 6 (31.6)
Living place
 Home 9 (47.4)
 Institution 9 (47.4)
 Not reported 1 (5.2)
Primary site
 Endometrium 6 (31.6)
 Cervix 6 (31.6)
 Vulva 4 (21.0)
 Vagina 3 (15.8)
Stage
 Localized (T1–T2 N0) 5 (26.3)
 Locally advanced (T3–T4 or N+) 10 (52.7)
 Metastatic 2 (10.5)
 Not reported 2 (10.5)
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and favor radiotherapy completion [9]. Our results sug-
gest that radiotherapy is feasible in nonagenarian patients 
with gynecologic cancer, but geriatric assessment could 
probably reduce treatment disruption and death rates. 
Although no consensus exists regarding the role of 
brachytherapy in the management of gynecologic can-
cer in patients 65 years of age or older, it should probably 
be considered a favorable option for geriatric patients 
because of its good results in terms of efficacy [10–12] 
and, when compared to external-beam radiotherapy, the 
fact that it causes fewer toxicities [11].
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